| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DS3 |
| Uniprot No | Q14952 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-245aa |
| 氨基酸序列 | HEGFRRKPSLLAHPGRLVKSEETVILQCWSDVMFEHFLLHREGTFNDTLRLIGEHIDGVSKANFSIGRMRQDLAGTYRCYGSVPHSPYQFSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSWSSYDMYHLSTEGEAHERRFSAGPKVNGTFQADFPLGPATQGGTYRCFGSFHDSPYEWSKSSDPLLVSVTGNPSNSWPSPTEPSSKTGNPRHLH |
| 预测分子量 | 26.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DS3重组蛋白的3篇参考文献示例，涵盖其功能、结构及临床关联研究：
---
1. **文献名称**：*"Functional Characterization of Recombinant KIR2DS3 Reveals Activation via HLA-C Ligands"*
**作者**：Parham P. et al.
**摘要**：本研究通过昆虫细胞系统表达重组KIR2DS3蛋白，验证其与HLA-C分子(如HLA-C1/C2)的相互作用。实验表明KIR2DS3结合特定HLA-C等位基因后可激活NK细胞杀伤功能，提示其在抗病毒免疫中的潜在作用。
2. **文献名称**：*"Structural Insights into KIR2DS3 Activation Mechanism through Recombinant Protein Crystallography"*
**作者**：Sundberg E.J. et al.
**摘要**：利用重组KIR2DS3蛋白进行X射线晶体学分析，解析其胞外结构域的三维构象。研究发现其D0结构域对配体识别至关重要，为设计靶向KIR2DS3的免疫调节药物提供结构基础。
3. **文献名称**：*"Association of Soluble KIR2DS3 Recombinant Protein with Autoimmune Disease Risk"*
**作者**：Kulkarni S. et al.
**摘要**：通过原核系统表达可溶性KIR2DS3重组蛋白，分析其在类风湿性关节炎患者血清中的结合特性。结果显示，KIR2DS3可能通过异常HLA识别参与自身免疫反应，为疾病生物标志物研究提供依据。
---
**备注**：上述文献为示例性质，实际研究可能需通过数据库(如PubMed)检索最新成果。若需具体文献，建议结合关键词“KIR2DS3 recombinant protein”或“KIR2DS3 expression”进一步筛选。
KIR2DS3 is a member of the killer-cell immunoglobulin-like receptor (KIR) family, which plays a critical role in regulating natural killer (NK) cell activity and adaptive immune responses. As an activating receptor, KIR2DS3 is characterized by two extracellular immunoglobulin-like domains (D0 and D2), a transmembrane region, and a short cytoplasmic tail lacking intrinsic signaling motifs. Instead, it associates with adaptor proteins like DAP12 to transmit activating signals through immunoreceptor tyrosine-based activation motifs (ITAMs). This receptor binds primarily to HLA-C molecules belonging to the HLA-C1 and HLA-C2 allelic groups, though interactions with non-classical HLA ligands or viral proteins have also been proposed.
Genetically, KIR2DS3 is located within the highly polymorphic KIR gene cluster on chromosome 19q13.4. Its presence has been linked to both protective and pathogenic outcomes in various diseases. For instance, certain KIR2DS3 polymorphisms correlate with improved antiviral responses in viral infections, while others associate with increased susceptibility to autoimmune disorders like rheumatoid arthritis or psoriasis. In cancer, KIR2DS3 expression may influence NK cell-mediated tumor surveillance, though its role remains context-dependent, varying by tumor type and HLA ligand availability.
Recombinant KIR2DS3 protein is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and structural fidelity. Bacterial systems may be employed for non-glycosylated forms used in structural studies. The purified protein often includes tags (e.g., Fc-fusion or His-tag) for detection and immobilization. Researchers utilize this recombinant protein to investigate ligand-receptor interactions, signal transduction mechanisms, and therapeutic modulation of NK cell activity. It serves as a tool for blocking experiments, structural analysis (X-ray crystallography/CRYO-EM), and developing immunotherapies aimed at enhancing NK cell function against malignancies or chronic infections. Its study contributes to understanding immune tolerance, transplantation compatibility, and personalized immunotherapy approaches.
×
